Want to see KROS full AI Analyst Report?

Keros Therapeutics (KROS) Stock Forecast & Price Target

365 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

KROS Analyst Ratings

Moderate Buy

4 Buy

4 Hold

0 Sell

Based on 8 analysts giving stock ratings to

Keros

Therapeutics

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

KROS Stock 12 Month Forecast

Average Price Target

$19.40

▲(92.84% Upside)

Based on 8 Wall Street analysts offering 12 month price targets for Keros Therapeutics in the last 3 months. The average price target is $19.40 with a high forecast of $23.00 and a low forecast of $16.00. The average price target represents a 92.84% change from the last price of $10.06.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"9":"$9","24":"$24","12.75":"$12.75","16.5":"$16.5","20.25":"$20.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":23,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$23.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":19.4,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$19.40</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":16,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$16.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[9,12.75,16.5,20.25,24],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2025","6":"Feb<br/>2026","9":"May<br/>2026","12":"Aug<br/>2026","25":"Aug<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,10.07,11.064615384615385,12.05923076923077,13.053846153846154,14.048461538461538,15.043076923076924,16.037692307692307,17.032307692307693,18.026923076923076,19.021538461538462,20.01615384615385,21.01076923076923,22.005384615384614,{"y":23,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,10.07,10.787692307692307,11.505384615384616,12.223076923076922,12.94076923076923,13.658461538461538,14.376153846153844,15.093846153846153,15.811538461538461,16.529230769230768,17.246923076923075,17.964615384615385,18.68230769230769,{"y":19.4,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,10.07,10.526153846153846,10.982307692307693,11.438461538461539,11.894615384615385,12.350769230769231,12.806923076923077,13.263076923076923,13.71923076923077,14.175384615384615,14.631538461538462,15.087692307692308,15.543846153846154,{"y":16,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":14.32,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.72,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.28,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.22,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":17.18,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":20.36,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":18.4,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.91,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.69,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.49,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.9,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.88,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.07,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$23.00

Average Price Target$19.40

Lowest Price Target$16.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Thomas Smith

Leerink Partners

$30→$23

Buy

128.63%

Upside

Reiterated

08/04/26

Keros Therapeutics price target lowered to $23 from $30 at LeerinkKeros Therapeutics price target lowered to $23 from $30 at Leerink

Andres Y. Maldonado

H.C. Wainwright

$20

Buy

98.81%

Upside

Reiterated

08/04/26

Analysts Are Bullish on Top Healthcare Stocks: Ocular Therapeutix (OCUL), Keros Therapeutics (KROS)

Matt Phipps

William Blair

―

Hold

―

Reiterated

08/04/26

Analysts Have Conflicting Sentiments on These Healthcare Companies: Relay Therapeutics (NASDAQ: RLAY) and Keros Therapeutics (NASDAQ: KROS)

Nicholas Lorusso

TD Cowen

―

Hold

―

Assigned

08/04/26

Analysts' Opinions Are Mixed on These Healthcare Stocks: Agios Pharma (NASDAQ: AGIO), Novavax (NASDAQ: NVAX) and Keros Therapeutics (NASDAQ: KROS)

Benjamin Burnett

Wells Fargo

$20→$18

Buy

78.93%

Upside

Assigned

08/03/26

Analysts Offer Insights on Healthcare Companies: Oric Pharmaceuticals (NASDAQ: ORIC), ClearPoint Neuro (NASDAQ: CLPT) and Keros Therapeutics (NASDAQ: KROS)

Jason Zemansky

Bank of America Securities

$20

Hold

98.81%

Upside

Reiterated

06/03/26

Bank of America Securities Reaffirms Their Hold Rating on Keros Therapeutics (KROS)

Yun Zhong

Wedbush

$16

Hold

59.05%

Upside

Reiterated

05/19/26

Hold Rating Reiterated on Keros as Takeda Partnership Progress Offsets Rinvatercept Delays; $16 Price Target Maintained

Srikripa Devarakonda

Truist Financial

―

Buy

―

Reiterated

05/15/26

Analysts Offer Insights on Healthcare Companies: Keros Therapeutics (NASDAQ: KROS), Cormedix (NASDAQ: CRMD) and Biogen (NASDAQ: BIIB)

Tiago Fauth

Raymond James

$23→$20

Buy

98.81%

Upside

Reiterated

03/05/26

Keros Therapeutics price target lowered to $20 from $23 at Wells FargoKeros Therapeutics price target lowered to $20 from $23 at Wells Fargo

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Thomas Smith

Leerink Partners

$30→$23

Buy

128.63%

Upside

Reiterated

08/04/26

Keros Therapeutics price target lowered to $23 from $30 at LeerinkKeros Therapeutics price target lowered to $23 from $30 at Leerink

Andres Y. Maldonado

H.C. Wainwright

$20

Buy

98.81%

Upside

Reiterated

08/04/26

Analysts Are Bullish on Top Healthcare Stocks: Ocular Therapeutix (OCUL), Keros Therapeutics (KROS)

Matt Phipps

William Blair

―

Hold

―

Reiterated

08/04/26

Analysts Have Conflicting Sentiments on These Healthcare Companies: Relay Therapeutics (NASDAQ: RLAY) and Keros Therapeutics (NASDAQ: KROS)

Nicholas Lorusso

TD Cowen

―

Hold

―

Assigned

08/04/26

Analysts' Opinions Are Mixed on These Healthcare Stocks: Agios Pharma (NASDAQ: AGIO), Novavax (NASDAQ: NVAX) and Keros Therapeutics (NASDAQ: KROS)

Benjamin Burnett

Wells Fargo

$20→$18

Buy

78.93%

Upside

Assigned

08/03/26

Analysts Offer Insights on Healthcare Companies: Oric Pharmaceuticals (NASDAQ: ORIC), ClearPoint Neuro (NASDAQ: CLPT) and Keros Therapeutics (NASDAQ: KROS)

Jason Zemansky

Bank of America Securities

$20

Hold

98.81%

Upside

Reiterated

06/03/26

Bank of America Securities Reaffirms Their Hold Rating on Keros Therapeutics (KROS)

Yun Zhong

Wedbush

$16

Hold

59.05%

Upside

Reiterated

05/19/26

Hold Rating Reiterated on Keros as Takeda Partnership Progress Offsets Rinvatercept Delays; $16 Price Target Maintained

Srikripa Devarakonda

Truist Financial

―

Buy

―

Reiterated

05/15/26

Analysts Offer Insights on Healthcare Companies: Keros Therapeutics (NASDAQ: KROS), Cormedix (NASDAQ: CRMD) and Biogen (NASDAQ: BIIB)

Tiago Fauth

Raymond James

$23→$20

Buy

98.81%

Upside

Reiterated

03/05/26

Keros Therapeutics price target lowered to $20 from $23 at Wells FargoKeros Therapeutics price target lowered to $20 from $23 at Wells Fargo

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

AVBPArriVent BioPharma, Inc.

BTSGBrightSpring Health Services, Inc.

MLYSMineralys Therapeutics, Inc.

AMLXAmylyx Pharmaceuticals Inc

ZURAZura Bio

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Keros Therapeutics

3 Months

Thomas SmithLeerink Partners

Success Rate

15/25 ratings generated profit

Average Return

+11.72%

Copying Thomas Smith's trades and holding each position for 3 Months would result in 60.00% of your transactions generating a profit, with an average return of +11.72% per trade.

1 Year

Srikripa DevarakondaTruist Financial

Success Rate

8/18 ratings generated profit

Average Return

-9.52%

Copying Srikripa Devarakonda's trades and holding each position for 1 Year would result in 44.44% of your transactions generating a profit, with an average return of -9.52% per trade.

2 Years

Thomas SmithLeerink Partners

Success Rate

3/25 ratings generated profit

Average Return

-44.91%

Copying Thomas Smith's trades and holding each position for 2 Years would result in 12.00% of your transactions generating a profit, with an average return of -44.91% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

KROS Analyst Recommendation Trends

Rating

Apr 26

May 26

Jun 26

Jul 26

Aug 26

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, KROS has received 3 Buy Ratings, 3 Hold Ratings, and 0 Sell Ratings. KROS average Analyst price target in the past 3 months is 19.40.

Each month's total comprises the sum of three months' worth of ratings.

KROS Financial Forecast

KROS Earnings Forecast

The previous quarter’s earnings for KROS were -$1.45.

KROS Sales Forecast

The previous quarter’s earnings for KROS were $0.00.

KROS Stock Forecast FAQ

What is KROS’s average 12-month price target, according to analysts?

Based on analyst ratings, Keros Therapeutics, Inc.’s 12-month average price target is 19.40.

What is KROS’s upside potential, based on the analysts’ average price target?

Keros Therapeutics, Inc. has 92.84% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is KROS a Buy, Sell or Hold?

Keros Therapeutics, Inc. has a consensus rating of Moderate Buy which is based on 4 buy ratings, 4 hold ratings and 0 sell ratings.

What is Keros Therapeutics, Inc.’s price target?

The average price target for Keros Therapeutics, Inc. is 19.40. This is based on 8 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $23.00 ,the lowest forecast is $16.00. The average price target represents 92.84% Increase from the current price of $10.06.

What do analysts say about Keros Therapeutics, Inc.?

Keros Therapeutics, Inc.’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 8 Wall Streets Analysts.

How can I buy shares of KROS?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Keros Therapeutics (KROS) Stock Forecast & Price Target

KROS Analyst Ratings

KROS Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Keros Therapeutics

KROS Analyst Recommendation Trends

KROS Financial Forecast

KROS Earnings Forecast

KROS Sales Forecast

KROS Stock Forecast FAQ

Detailed List of Analyst Forecasts